Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Authors
Moshe E. Gatt (ORCID: https://orcid.org/0000-0002-9426-4482)
Emma Scott (ORCID: https://orcid.org/0000-0001-7854-9982)
Nicholas T. Au
Michael Chu
Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Moshe E. Gatt, Emma Scott, Nicholas T. Au, Michael Chu et al.
Journal
Blood
Topics
Multiple Myeloma Research and Treatments
article
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Moshe E. Gatt, Emma Scott, Nicholas T. Au, Michael Chu, Saad Z. Usmani, M Festa, Todd Henninger, María‐Victoria Mateos, Shahzad Raza, Hila Magen, Shebli Atrash, Dok Hyun Yoon, Eva Medvedova, Laura Rosiñol Dachs, Tadao Ishida, Yael Chava Cohen, Paula Rodríguez‐Otero, Suzanne Trudel, Christoph Heuck, Maria Krevvata, Jiashen Lu, Hang Quach, Lin Huang, Lixia Pei, Jing Zhang, Joshua R. Richter, J Christine Ye, Lisa O’Rourke, Hun Chuah, Shaji Kumar, Jeffrey Matous, Koichi Onodera, Jiangxiu Zhou, Mikihiro Takamoto, Payal Thakkar, Carmela Maffucci
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Alberta Health Services (CA), Cleveland Clinic (US), Mount Sinai Hospital (US), Sendai University (JP), Johnson & Johnson (United States) (US), The University of Texas MD Anderson Cancer Center (US), Rochester Institute of Technology (US), Oregon Health & Science University (US), Hebrew University of Jerusalem (IL), Royal Perth Hospital (AU), Tel Aviv Sourasky Medical Center (IL), Sheba Medical Center (IL), Hadassah Medical Center (IL), Princess Margaret Cancer Centre (CA), Kettering University (US), University of Ulsan (KR), St Vincent's Hospital Melbourne (AU), Mount Sinai Medical Center (US), Levine Cancer Institute (US), Sarah Cannon (US), Japanese Red Cross Medical Center (JP), Hospital Clínic de Barcelona (ES), Instituto de Investigación Biomédica de Salamanca (ES), Colorado Blood Cancer Institute (US), Clinica Universidad de Navarra (ES), Centro de Investigación del Cáncer (ES), Alberta Health (CA), Johnson & Johnson (United Kingdom) (GB), Johnson & Johnson (Netherlands) (NL), Centro de Investigación Biomédica en Red de Cáncer (ES), Johnson & Johnson (Brazil) (BR)